Search PubMed⌕ Search

Biomedical subjects

M Frank

Publications and source records attributed to M Frank.

349 records · Page 20Linked to original sources
PubMedDate not supplied

Moclobemide enhances aversively motivated learning and memory in rats.

Moclobemide belongs to a new class of short-acting reversible monoamine oxidase type A inhibitors with antidepressant activity. Male Wistar rats (180-220 g) were administered single and multiple (14x, daily) intragastrical doses of 20 mg/kg of moclobemide. The effects of the drug on the acquisition of conditioned avoidance responses (CARs), retrieval of passive avoidance, recognition memory, psychomotor activity in open field, and level of anxiety in an elevated "plus" maze were assessed. Moclobemide, given repeatedly, increased rate of the CAR acquisition, retrieval of the passive avoidance and had some anxiolytic properties. The drug, however, did not influence rats' psychomotor activity tested in open field and their ability to discriminate between familiar and unfamiliar objects. The results show that moclobemide in rats, given chronically, enhances aversively motivated learning and does not influence recognition.

Animals↗
PubMedDate not supplied

[Prematurity and prenatal care].

In regard of the constant rate of low birthweight infants in Federal Republic of Germany kinds and relevance of social factors within Low Birthweight are examined. Results of a study based on all births in Berlin (West) during the years 1982-1985 (n = 72201) are presented. It shows a constant rate of low birthweight infants also in Berlin (mean: 6.3%, excluding multiple births). Several social factors (legitimacy, nationality...) with varying intensity played a major role, especially if certain risk situations were cumulating. Since Prenatal Care has particular difficulties in reaching women at higher risks early and consequently, specific approaches of intervention derived from experiences in the US are suggested.

Adolescent↗
PubMedDate not supplied

Caring for day care: a pilot project.

Day care in Israel is not always of high quality, and the current forecast for upgrading the standards of the existing centers is bleak, due to economic and social factors that do not place high priority on quality infant care in group settings. The agency attempted, therefore, to develop a low-cost, efficient method of early intervention, wherein skilled social workers were hired, given special training, and worked alongside the caregivers of day care centers to help children and parents defined as at risk. This article describes the observations that were made and the interventions that were chosen.

Child Day Care Centers↗
PubMedDate not supplied

Mitoxantrone, vinblastine, and lomustine (CCNU) (MVC): a highly active regimen for advanced and poor-prognosis Hodgkin's disease.

PURPOSE: A new regimen, MVC (mitoxantrone, vinblastine, and CCNU [lomustine]), was studied in advanced Hodgkin's disease. This regimen combines the most effective elements of previous regimens for poor-prognosis Hodgkin's disease and eliminates agents with unnecessary toxicities and marginal activity. Initially, patients with relapsed or refractory disease were entered, and after substantial activity was observed, patients with advanced-stage, newly diagnosed Hodgkin's disease were also treated. PATIENTS AND METHODS: Thirty-six relapsed or refractory patients were entered on this study. Prior treatment included radiotherapy alone (three patients), combined-modality treatment (n = 21), and single (n = 2) or multiple chemotherapy regimens (n = 10). Seventeen advanced-stage (bulky IIB-IVB) newly diagnosed Hodgkin's patients were also entered, with a median follow-up of 7 years. RESULTS: Thirty-two of 36 (88%) relapsed/refractory patients responded to MVC, with 18 partial responses (50%) and 14 complete responses (39%). Median complete response duration is 20 months (range, 2 to 108+ months). The median survival of all previously treated MVC patients is 28 months (range, 4 to 127+ months). Eleven of 32 previously treated MVC responders remain alive and disease-free at 12 to 127+ months, seven after autologous bone marrow transplantation (12 to 127+ months) and four after MVC without transplantation (31 to 113+ months). Thirteen of 17 advanced-stage, newly diagnosed Hodgkin's disease patients achieved a complete response and four achieved a partial response to MVC (100% response rate). Two complete response and all partial response patients have relapsed. Eight complete responses are ongoing at 11 to 114+ months. Three patients died in complete response at 11, 42, and 43 months. Median response duration has not been reached. DISCUSSION: MVC is a highly active regimen in relapsed and advanced-stage Hodgkin's disease, with outcome results comparable to other established regimens. Treatment is associated with myelosuppression but is otherwise well tolerated. MVC provides an effective alternative regimen for newly diagnosed patients with Hodgkin's disease and an effective salvage regimen for patients previously treated with anthracyclines.

Adult↗